Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Constantine S. Tam, Susan O'Brien, William Plunkett, William Wierda, Alessandra Ferrajoli, Xuemei Wang, Kim Anh Do, Jorge Cortes, Issa Khouri, Hagop Kantarjian, Susan Lerner, Michael J. Keating

Research output: Contribution to journalArticle

Abstract

Although fludarabine, cyclophosphamide, and rituximab (FCR) together are established as a standard first-line treatment of younger patients with chronic lymphocytic leukemia (CLL), there is little information to guide the management of patients with CLL refractory to, or who have relapsed after, receiving frontline FCR treatment. To define optimal salvage strategy and identify patients unsuitable for retreatment with FCR, we examined the survival and treatment outcome of 300 patients enrolled in a phase 2 study of FCR. After a median 142 months of follow-up, 156 patients developed progressive CLL, with a median survival of 51 months after disease progression. The durationof first remission (REM1) was a key determinant of survival after disease progression and first salvage. Patients with a short REM1 (<3 years) had a short survival period, irrespective of salvage therapy received; these patients have high unmet medical needs and are good candidates for investigationofnovel therapies. Inpatients withalong REM1 (≥3 years),salvage treatment with either repeat FCR or lenalidomide-based therapy results in subsequent median survival exceeding 5 years; for these patients, FCR rechallenge represents a reasonable standard of care.

Original languageEnglish (US)
Pages (from-to)3059-3064
Number of pages6
JournalBlood
Volume124
Issue number20
DOIs
StatePublished - Nov 13 2014

Fingerprint

Salvaging
Salvage Therapy
B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Survival
Disease Progression
Refractory materials
Retreatment
fludarabine
Rituximab
Therapeutics
Standard of Care
Inpatients

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Tam, C. S., O'Brien, S., Plunkett, W., Wierda, W., Ferrajoli, A., Wang, X., ... Keating, M. J. (2014). Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood, 124(20), 3059-3064. https://doi.org/10.1182/blood-2014-06-583765

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). / Tam, Constantine S.; O'Brien, Susan; Plunkett, William; Wierda, William; Ferrajoli, Alessandra; Wang, Xuemei; Do, Kim Anh; Cortes, Jorge; Khouri, Issa; Kantarjian, Hagop; Lerner, Susan; Keating, Michael J.

In: Blood, Vol. 124, No. 20, 13.11.2014, p. 3059-3064.

Research output: Contribution to journalArticle

Tam, CS, O'Brien, S, Plunkett, W, Wierda, W, Ferrajoli, A, Wang, X, Do, KA, Cortes, J, Khouri, I, Kantarjian, H, Lerner, S & Keating, MJ 2014, 'Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)', Blood, vol. 124, no. 20, pp. 3059-3064. https://doi.org/10.1182/blood-2014-06-583765
Tam, Constantine S. ; O'Brien, Susan ; Plunkett, William ; Wierda, William ; Ferrajoli, Alessandra ; Wang, Xuemei ; Do, Kim Anh ; Cortes, Jorge ; Khouri, Issa ; Kantarjian, Hagop ; Lerner, Susan ; Keating, Michael J. / Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). In: Blood. 2014 ; Vol. 124, No. 20. pp. 3059-3064.
@article{54561b591c3b4ccdb8f3eeff9a81fb8b,
title = "Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)",
abstract = "Although fludarabine, cyclophosphamide, and rituximab (FCR) together are established as a standard first-line treatment of younger patients with chronic lymphocytic leukemia (CLL), there is little information to guide the management of patients with CLL refractory to, or who have relapsed after, receiving frontline FCR treatment. To define optimal salvage strategy and identify patients unsuitable for retreatment with FCR, we examined the survival and treatment outcome of 300 patients enrolled in a phase 2 study of FCR. After a median 142 months of follow-up, 156 patients developed progressive CLL, with a median survival of 51 months after disease progression. The durationof first remission (REM1) was a key determinant of survival after disease progression and first salvage. Patients with a short REM1 (<3 years) had a short survival period, irrespective of salvage therapy received; these patients have high unmet medical needs and are good candidates for investigationofnovel therapies. Inpatients withalong REM1 (≥3 years),salvage treatment with either repeat FCR or lenalidomide-based therapy results in subsequent median survival exceeding 5 years; for these patients, FCR rechallenge represents a reasonable standard of care.",
author = "Tam, {Constantine S.} and Susan O'Brien and William Plunkett and William Wierda and Alessandra Ferrajoli and Xuemei Wang and Do, {Kim Anh} and Jorge Cortes and Issa Khouri and Hagop Kantarjian and Susan Lerner and Keating, {Michael J.}",
year = "2014",
month = "11",
day = "13",
doi = "10.1182/blood-2014-06-583765",
language = "English (US)",
volume = "124",
pages = "3059--3064",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

AU - Tam, Constantine S.

AU - O'Brien, Susan

AU - Plunkett, William

AU - Wierda, William

AU - Ferrajoli, Alessandra

AU - Wang, Xuemei

AU - Do, Kim Anh

AU - Cortes, Jorge

AU - Khouri, Issa

AU - Kantarjian, Hagop

AU - Lerner, Susan

AU - Keating, Michael J.

PY - 2014/11/13

Y1 - 2014/11/13

N2 - Although fludarabine, cyclophosphamide, and rituximab (FCR) together are established as a standard first-line treatment of younger patients with chronic lymphocytic leukemia (CLL), there is little information to guide the management of patients with CLL refractory to, or who have relapsed after, receiving frontline FCR treatment. To define optimal salvage strategy and identify patients unsuitable for retreatment with FCR, we examined the survival and treatment outcome of 300 patients enrolled in a phase 2 study of FCR. After a median 142 months of follow-up, 156 patients developed progressive CLL, with a median survival of 51 months after disease progression. The durationof first remission (REM1) was a key determinant of survival after disease progression and first salvage. Patients with a short REM1 (<3 years) had a short survival period, irrespective of salvage therapy received; these patients have high unmet medical needs and are good candidates for investigationofnovel therapies. Inpatients withalong REM1 (≥3 years),salvage treatment with either repeat FCR or lenalidomide-based therapy results in subsequent median survival exceeding 5 years; for these patients, FCR rechallenge represents a reasonable standard of care.

AB - Although fludarabine, cyclophosphamide, and rituximab (FCR) together are established as a standard first-line treatment of younger patients with chronic lymphocytic leukemia (CLL), there is little information to guide the management of patients with CLL refractory to, or who have relapsed after, receiving frontline FCR treatment. To define optimal salvage strategy and identify patients unsuitable for retreatment with FCR, we examined the survival and treatment outcome of 300 patients enrolled in a phase 2 study of FCR. After a median 142 months of follow-up, 156 patients developed progressive CLL, with a median survival of 51 months after disease progression. The durationof first remission (REM1) was a key determinant of survival after disease progression and first salvage. Patients with a short REM1 (<3 years) had a short survival period, irrespective of salvage therapy received; these patients have high unmet medical needs and are good candidates for investigationofnovel therapies. Inpatients withalong REM1 (≥3 years),salvage treatment with either repeat FCR or lenalidomide-based therapy results in subsequent median survival exceeding 5 years; for these patients, FCR rechallenge represents a reasonable standard of care.

UR - http://www.scopus.com/inward/record.url?scp=84911933713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911933713&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-06-583765

DO - 10.1182/blood-2014-06-583765

M3 - Article

C2 - 25281606

AN - SCOPUS:84911933713

VL - 124

SP - 3059

EP - 3064

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -